Corvus Pharmaceuticals Inc
CRVS
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.1B
Close$
$0.05
99.7% downside
Current Fair Value
99.7% downsideOvervalued by 99.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.10 Billion |
|---|---|
| Enterprise Value | $1.06 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.19 |
| Beta | 0.82 |
| Outstanding Shares | 89,996,728 |
Return
| Return on Equity | -18.35% |
|---|---|
| Return on Assets | -17.44% |
| Return on Invested Capital | -20.06% |
Valuation & Multiples
| P/E Ratio | -23.76 |
|---|---|
| PEG | 12.5 |
| Price to Sales | - |
| Price to Book Ratio | 6.52 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -21.91 |
| Enterprise Value to Net Income | -24 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.14
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.17
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 33.24% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.41%▼ 88.21% |
|---|---|
| Total Invested | $5.27M▼ 99.48% |
| Investors Holding | 16▼ 157.00% |
ESG Score
No data
About Corvus Pharmaceuticals Inc
CEO: Richard Miller